GALAD (Gender, age, AFP-L3, AFP, and des-carboxy-prothrombin [DCP]), a promising biomarker panel is proved to be excellent for early detection of HCC in NAFLD/NASH patients with and without HCC and GALAD is significantly superior to each individual marker [67]. The gene discussed is AFP; the disease is metabolic dysfunction-associated steatotic liver disease.